LATHAM, N.Y. / Mar 31, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, will host a virtual cardiovascular investor event this Wednesday, April 2, 2025 at 9:00am ET. The event will take place immediately following the Company’s Fiscal 2025 Third Quarter Financial Results Conference Call which will start at 8:00am ET the same day.
Virtual Cardiovascular Investor Event
Date: Wednesday, April 2, 2025
Time: 9:00am ET
Duration: 60 minutes
Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei=1712212&tp_key=cedf6b19b1
Event Overview
AngioDynamics will provide investors a deeper dive into the cardiovascular technology portfolio and strategic vision.
The event will be webcast and can be accessed through the "Investors" section of the AngioDynamics website at www.angiodynamics.com.
About AngioDynamics, Inc.
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.
The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.
| Last Trade: | US$12.40 |
| Daily Change: | 0.10 0.81 |
| Daily Volume: | 297,862 |
| Market Cap: | US$510.880M |
October 02, 2025 July 28, 2025 July 23, 2025 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load